Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

ITI-1284 clinical trials

Also listed in trial records as JNJ-99245354
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 6 trials in our USA, Czechia, Poland, Spain and Italy registers that name ITI-1284 as an intervention. Synced 10 Nov 2026
6Current trials
6Recruiting now
1Lead sponsor
5Country registers
At a glance

ITI-1284 is named as an intervention in 6 current clinical trials in our USA, Czechia, Poland, Spain and Italy registers. 6 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is Intra-Cellular Therapies, Inc. The most-studied condition is Generalized Anxiety Disorder.

Patient leaflets for ITI-1284

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting6100%

Trials by phase

  • Phase 2467%
  • Phase 3233%
01

Clinical trials of ITI-1284

6 trials
StudyPhaseStatusLead sponsorRegisters
A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)
NCT07807865 · ClinicalTrials.gov ↗ · Generalized Anxiety Disorder
Phase 3 Recruiting Intra-Cellular Therapies, Inc USA
A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment
NCT07856420 · ClinicalTrials.gov ↗ · Generalized Anxiety Disorder
Phase 3 Recruiting Intra-Cellular Therapies, Inc USA
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383 · Generalized Anxiety Disorder
Phase 2 Recruiting Intra-Cellular Therapies, Inc USA, Poland, Czechia
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833 · Psychotic Disorders, Alzheimer Disease
Phase 2 Recruiting Intra-Cellular Therapies, Inc USA, Spain, Italy, Poland, Czechia
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567 · Agitation Associated With Alzheimer's Dementia
Phase 2 Recruiting Intra-Cellular Therapies, Inc USA, Spain, Czechia
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
NCT06701903 · Generalized Anxiety Disorder
Phase 2 Recruiting Intra-Cellular Therapies, Inc USA, Poland

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with ITI-1284

4 conditions
Generalized Anxiety Disorder4Agitation Associated With Alzheimer's Dementia1Psychotic Disorders1Alzheimer Disease1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Intra-Cellular Therapies, Inc6
04

By country register

RegisterTrialsRecruiting
Clinical trials in USA66
Clinical trials in Czechia33
Clinical trials in Poland33
Clinical trials in Spain22
Clinical trials in Italy11

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about ITI-1284 trials

How many clinical trials are testing ITI-1284?

6 current trials in our USA, Czechia, Poland, Spain and Italy registers name ITI-1284 (also registered as JNJ-99245354) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are ITI-1284 trials recruiting patients?

Yes. 6 of the 6 trials are recruiting: 6 with sites in USA, 3 with sites in Czechia, 3 with sites in Poland, 2 with sites in Spain and 1 with sites in Italy. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors ITI-1284 clinical trials?

The lead sponsor is Intra-Cellular Therapies, Inc. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ITI-1284 works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ITI-1284 works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ITI-1284 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.